نتایج جستجو برای: hematological toxicities

تعداد نتایج: 51579  

Journal: :Anticancer research 2015
Akinobu Tawada Tetsuhiro Chiba Yoshihiko Ooka Naoya Kanogawa Tomoko Saito Tenyu Motoyama Sadahisa Ogasawara Eiichiro Suzuki Fumihiko Kanai Masaharu Yoshikawa Osamu Yokosuka

AIM We aimed to evaluate the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) using miriplatin plus epirubicin in unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS The efficacy of TACE was evaluated by dynamic computed tomography (CT) or magnetic resonance imaging (MRI) three months after the procedure according to the Response Evaluation Criteria in Can...

2017
Yujiro Naito Akihiro Tamiya Motohiro Tamiya Yohei Kimura Masanari Hamaguchi Nobuhiko Saijo Masaki Kanazu Sayoko Tokura Takayuki Shiroyama Naoko Morisita Naoki Omachi Hidekazu Suzuki Norio Okamoto Kyoichi Okishio Tomonori Hirashima Shinji Atagi

Although small cell lung cancer (SCLC) is initially sensitive to chemotherapy, it recurs in most cases. Standard regimens for salvage chemotherapy have not been established, and the prognosis of relapsed SCLC remains poor. In the present study, we investigated the clinical efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) regimens for the treatment of relapsed SCLC.I...

2015
Jing Yu Jing Xiao Yifan Yang Bangwei Cao Yang Liu.

The efficacy and toxicity of oxaliplatin-based versus carboplatin/cisplatin-based doublets in patients with previously untreated nonsmall cell lung cancer (NSCLC) have been compared.We searched published randomized controlled trials of oxaliplatin-based or carboplatin/cisplatin-based medications for NSCLC. A fixed effect model was used to analyze outcomes which were expressed as the hazard rati...

Journal: :Anti-cancer drugs 2004
Sergio Vázquez Carlos Grande Margarita Amenedo José Luis Fírvida Martín Lázaro Guillermo Alonso Teresa Curiel Gerardo Huidobro José Ramón Mel Manuel Ramos

This phase II trial assessed the antitumoral activity and toxicity of docetaxel 50 mg/m (1-h i.v. infusion) administered every 2 weeks as second-line treatment in 45 patients with advanced non-small cell lung cancer (NSCLC). A total of 251 infusions (median 4 per patient) were administered. The actual and relative median dose intensity values were 24.2 mg/m/week and 0.97, respectively. Thirty-s...

2016
Xiaoliang Zhao Yanjun Su Jian You Liqun Gong Zhenfa Zhang Meng Wang Zhenqing Zhao Zhen Zhang Xiaolin Li Changli Wang

To evaluate the safety and efficacy of combining Endostar antiangiogenic therapy with neoadjuvant chemotherapy for the treatment of stage IIIA (N2) NSCLC, we conducted a randomized, controlled, open-label clinical study of 30 NSCLC patients. Patients were randomly assigned to the test or control groups, which received either two cycles of an NP neoadjuvant chemotherapy regimen combined with End...

2016
Zhi-Qiang Wang Dong-Sheng Zhang Nong Xu De-Yun Luo Yan-Hong Deng Feng-Hua Wang Hui-Yan Luo Miao-Zhen Qiu Yu-Hong Li Rui-Hua Xu

BACKGROUND Fluoropyrimidine and oxaliplatin are widely used for patients with colorectal cancer. This phase II study was conducted to evaluate the efficacy and safety of the combination of S-1, oxaliplatin, and leucovorin (SOL) in the treatment of Chinese patients with metastatic colorectal cancer (mCRC). METHODS Eligible patients with untreated mCRC from four hospitals in China received intr...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2004
Yukito Ichinose Yushi Nakai Shoji Kudoh Hiroshi Semba Susumu Yoshida Toshihiro Nukiwa Hidehiko Yamamoto Yoshio Yamane Hisanobu Niitani

PURPOSE To evaluate the efficacy and toxicity of a novel combination treatment using concurrent radiotherapy with cisplatin plus UFT, which is comprised of uracil and tegafur, in locally advanced non-small cell lung cancer (NSCLC) patients. EXPERIMENTAL DESIGN In this Phase II trial, patients with unresectable stage III NSCLC were treated with the oral administration of UFT (400 mg/m(2)/d teg...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2003
K A Gelmon T A Vandenberg L Panasci B Norris M Crump L Douglas W Walsh S J Matthews L K Seymour

BACKGROUND ZD0473 is a new generation platinum compound with activity against a wide range of human tumor cell lines and xenografts, including carboplatin- and cisplatin-resistant lines. A phase II study of ZD0473 in advanced breast cancer was initiated by the National Cancer Institute of Canada Clinical Trials Group. PATIENTS AND METHODS Women with metastatic breast cancer, measurable diseas...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2001
S D Gore L J Weng S Zhai W D Figg R C Donehower G J Dover M Grever C A Griffin L B Grochow E K Rowinsky Y Zabalena A L Hawkins K Burks C B Miller

Sodium phenylbutyrate (PB) is an aromatic fatty acid with cytostatic and differentiating activity against malignant myeloid cells (ID(50), 1-2 mM). Higher doses induce apoptosis. Patients with myelodysplasia (n = 11) and acute myeloid leukemia (n = 16) were treated with PB as a 7-day continuous infusion repeated every 28 days in a Phase I dose escalation study. The maximum tolerated dose was 37...

Journal: :American journal of blood research 2012
Seah H Lim Yana Zhang Jian Zhang

Immunotherapy is theoretically an attractive therapeutic option for patients with hematological malignancies. Various laboratory studies suggested the importance of the choice of tumor antigen for successful immunotherapy. Cancer-testis antigens (CTAs) are potentially suitable molecules for tumor vaccines of hematological malignancies because of their high immunogenicity in vivo, even in cancer...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید